Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Neurofibromatosis 1 | 50 | 2024 | 570 | 9.340 |
Why?
|
Optic Nerve Glioma | 7 | 2024 | 32 | 2.540 |
Why?
|
Brain Neoplasms | 29 | 2024 | 8861 | 1.830 |
Why?
|
Progeria | 6 | 2016 | 185 | 1.770 |
Why?
|
Neurofibroma, Plexiform | 9 | 2022 | 71 | 1.720 |
Why?
|
Neurofibromatoses | 10 | 2023 | 299 | 1.200 |
Why?
|
Neurocutaneous Syndromes | 2 | 2015 | 51 | 1.000 |
Why?
|
Moyamoya Disease | 4 | 2013 | 238 | 0.980 |
Why?
|
School Health Services | 2 | 2018 | 375 | 0.960 |
Why?
|
Cranial Irradiation | 5 | 2022 | 401 | 0.940 |
Why?
|
Neurofibromatosis 2 | 7 | 2023 | 380 | 0.930 |
Why?
|
Craniopharyngioma | 5 | 2020 | 281 | 0.910 |
Why?
|
Nervous System Diseases | 5 | 2017 | 1622 | 0.910 |
Why?
|
Radiation Injuries | 3 | 2018 | 1180 | 0.900 |
Why?
|
Child | 92 | 2024 | 77709 | 0.900 |
Why?
|
Glioma | 11 | 2020 | 3401 | 0.820 |
Why?
|
Neurilemmoma | 8 | 2023 | 547 | 0.810 |
Why?
|
Radiotherapy | 7 | 2017 | 1533 | 0.780 |
Why?
|
Survivors | 12 | 2023 | 2291 | 0.780 |
Why?
|
Brain Stem Neoplasms | 3 | 2015 | 204 | 0.760 |
Why?
|
Nerve Sheath Neoplasms | 3 | 2023 | 191 | 0.750 |
Why?
|
Cell Adhesion Molecules | 2 | 2015 | 1602 | 0.670 |
Why?
|
Antineoplastic Agents | 11 | 2020 | 13693 | 0.660 |
Why?
|
Child, Preschool | 46 | 2021 | 41005 | 0.660 |
Why?
|
Neoplasms | 18 | 2023 | 21696 | 0.650 |
Why?
|
Medulloblastoma | 4 | 2017 | 683 | 0.650 |
Why?
|
Neurology | 2 | 2020 | 763 | 0.640 |
Why?
|
Adolescent | 68 | 2024 | 85779 | 0.640 |
Why?
|
Visual Acuity | 5 | 2020 | 2530 | 0.620 |
Why?
|
Infratentorial Neoplasms | 3 | 2017 | 94 | 0.610 |
Why?
|
Neurofibromin 1 | 4 | 2020 | 196 | 0.610 |
Why?
|
Seizures | 7 | 2024 | 2859 | 0.600 |
Why?
|
Clitoris | 1 | 2017 | 33 | 0.590 |
Why?
|
Diabetes Insipidus | 2 | 2019 | 151 | 0.590 |
Why?
|
Spasm | 1 | 2017 | 121 | 0.590 |
Why?
|
Neurotoxicity Syndromes | 1 | 2021 | 290 | 0.590 |
Why?
|
Chloride Channels | 5 | 1998 | 227 | 0.560 |
Why?
|
Ependymoma | 5 | 2021 | 334 | 0.550 |
Why?
|
Central Nervous System Neoplasms | 5 | 2023 | 895 | 0.550 |
Why?
|
Glioblastoma | 8 | 2010 | 3481 | 0.540 |
Why?
|
Paresis | 1 | 2017 | 179 | 0.540 |
Why?
|
Medical Oncology | 3 | 2023 | 2267 | 0.520 |
Why?
|
Disabled Children | 1 | 2018 | 247 | 0.520 |
Why?
|
Leukemia, B-Cell | 1 | 2015 | 86 | 0.520 |
Why?
|
Vitamin B 12 Deficiency | 1 | 2016 | 116 | 0.510 |
Why?
|
Brain Abscess | 1 | 2015 | 118 | 0.500 |
Why?
|
Antigens, CD | 2 | 2015 | 4026 | 0.490 |
Why?
|
Astrocytoma | 7 | 2017 | 790 | 0.480 |
Why?
|
Mutism | 1 | 2014 | 24 | 0.480 |
Why?
|
Thorax | 1 | 2017 | 547 | 0.470 |
Why?
|
Stroke | 5 | 2023 | 9981 | 0.470 |
Why?
|
Microphthalmia-Associated Transcription Factor | 1 | 2015 | 252 | 0.460 |
Why?
|
Infant | 31 | 2021 | 35134 | 0.460 |
Why?
|
Epilepsy | 3 | 2024 | 3310 | 0.460 |
Why?
|
Gram-Positive Bacterial Infections | 1 | 2015 | 341 | 0.430 |
Why?
|
Humans | 139 | 2024 | 744366 | 0.430 |
Why?
|
Pituitary Diseases | 1 | 2013 | 141 | 0.410 |
Why?
|
Bone Diseases, Developmental | 1 | 2013 | 130 | 0.410 |
Why?
|
Piperidines | 4 | 2016 | 1602 | 0.410 |
Why?
|
Neurofibrosarcoma | 2 | 2023 | 24 | 0.400 |
Why?
|
Neuroectodermal Tumors, Primitive | 2 | 2017 | 140 | 0.400 |
Why?
|
Neuropsychological Tests | 6 | 2020 | 6994 | 0.400 |
Why?
|
Pyridines | 4 | 2021 | 2825 | 0.390 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2022 | 3255 | 0.380 |
Why?
|
Male | 75 | 2024 | 350115 | 0.370 |
Why?
|
Cerebral Revascularization | 1 | 2013 | 238 | 0.370 |
Why?
|
Pituitary Gland | 1 | 2013 | 665 | 0.360 |
Why?
|
Lovastatin | 3 | 2020 | 120 | 0.360 |
Why?
|
Eye Abnormalities | 1 | 2012 | 246 | 0.360 |
Why?
|
Delphi Technique | 3 | 2023 | 779 | 0.350 |
Why?
|
Skin Neoplasms | 9 | 2023 | 5692 | 0.340 |
Why?
|
Craniofacial Abnormalities | 1 | 2012 | 315 | 0.340 |
Why?
|
Female | 72 | 2024 | 380193 | 0.330 |
Why?
|
Acupressure | 2 | 2018 | 16 | 0.330 |
Why?
|
Consensus | 7 | 2023 | 2960 | 0.320 |
Why?
|
Skull | 1 | 2013 | 814 | 0.320 |
Why?
|
Optic Disk | 1 | 2012 | 400 | 0.320 |
Why?
|
Angiogenesis Inhibitors | 3 | 2019 | 2038 | 0.300 |
Why?
|
Neuroma, Acoustic | 2 | 2023 | 451 | 0.300 |
Why?
|
Play and Playthings | 1 | 2008 | 79 | 0.300 |
Why?
|
Young Adult | 32 | 2023 | 56429 | 0.300 |
Why?
|
Memory Disorders | 2 | 2017 | 1186 | 0.300 |
Why?
|
Medical Records | 1 | 2013 | 1413 | 0.300 |
Why?
|
Parents | 2 | 2018 | 3405 | 0.300 |
Why?
|
Pseudotumor Cerebri | 1 | 2008 | 100 | 0.300 |
Why?
|
Retrospective Studies | 30 | 2021 | 77460 | 0.290 |
Why?
|
Angiography | 1 | 2012 | 1639 | 0.290 |
Why?
|
Brain Damage, Chronic | 1 | 2008 | 265 | 0.290 |
Why?
|
Melanoma | 2 | 2015 | 5511 | 0.290 |
Why?
|
Neurosurgical Procedures | 6 | 2024 | 2002 | 0.280 |
Why?
|
Myelitis, Transverse | 1 | 2006 | 39 | 0.280 |
Why?
|
Killer Cells, Natural | 1 | 2015 | 2133 | 0.270 |
Why?
|
Cerebrovascular Disorders | 1 | 2012 | 1504 | 0.260 |
Why?
|
Neoplastic Syndromes, Hereditary | 1 | 2008 | 241 | 0.260 |
Why?
|
Nausea | 2 | 2018 | 674 | 0.260 |
Why?
|
Referral and Consultation | 1 | 2018 | 3531 | 0.250 |
Why?
|
Migraine Disorders | 1 | 2017 | 1620 | 0.250 |
Why?
|
Diagnosis, Computer-Assisted | 1 | 2010 | 719 | 0.250 |
Why?
|
Patient Education as Topic | 2 | 2014 | 2278 | 0.250 |
Why?
|
Pituitary Neoplasms | 3 | 2020 | 1345 | 0.250 |
Why?
|
Hearing Loss | 2 | 2023 | 765 | 0.250 |
Why?
|
Cerebral Arteries | 1 | 2007 | 494 | 0.250 |
Why?
|
Quality of Life | 11 | 2023 | 12802 | 0.240 |
Why?
|
Internship and Residency | 2 | 2020 | 5791 | 0.240 |
Why?
|
Motor Skills Disorders | 1 | 2004 | 90 | 0.240 |
Why?
|
Hypothalamic Diseases | 1 | 2005 | 135 | 0.230 |
Why?
|
Amnesia, Transient Global | 1 | 2003 | 22 | 0.230 |
Why?
|
Genetic Association Studies | 5 | 2019 | 2703 | 0.230 |
Why?
|
Cisplatin | 2 | 2020 | 1662 | 0.230 |
Why?
|
Vision Disorders | 3 | 2016 | 1058 | 0.220 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2012 | 2016 | 0.220 |
Why?
|
Diagnosis, Differential | 8 | 2019 | 12961 | 0.220 |
Why?
|
User-Computer Interface | 1 | 2010 | 1431 | 0.220 |
Why?
|
Airway Obstruction | 1 | 2008 | 664 | 0.220 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 2 | 2022 | 647 | 0.210 |
Why?
|
Disability Evaluation | 1 | 2010 | 1828 | 0.210 |
Why?
|
Electroencephalography | 4 | 2017 | 6151 | 0.210 |
Why?
|
Pediatrics | 4 | 2020 | 3475 | 0.200 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2012 | 2943 | 0.200 |
Why?
|
Developmental Disabilities | 2 | 2008 | 1456 | 0.200 |
Why?
|
Cafe-au-Lait Spots | 2 | 2021 | 18 | 0.200 |
Why?
|
Mutation, Missense | 3 | 2019 | 2566 | 0.190 |
Why?
|
Pseudarthrosis | 1 | 2021 | 59 | 0.190 |
Why?
|
Clinical Trials as Topic | 5 | 2019 | 7914 | 0.190 |
Why?
|
Thiosulfates | 1 | 2020 | 52 | 0.190 |
Why?
|
Sirolimus | 2 | 2020 | 1565 | 0.180 |
Why?
|
Adult | 32 | 2024 | 214052 | 0.180 |
Why?
|
Treatment Outcome | 16 | 2023 | 63107 | 0.180 |
Why?
|
Supratentorial Neoplasms | 2 | 2019 | 160 | 0.180 |
Why?
|
Bone Morphogenetic Protein 2 | 1 | 2021 | 350 | 0.170 |
Why?
|
Education, Medical, Graduate | 1 | 2011 | 2291 | 0.170 |
Why?
|
Cognition Disorders | 2 | 2012 | 4043 | 0.160 |
Why?
|
Practice Guidelines as Topic | 3 | 2021 | 7282 | 0.160 |
Why?
|
Maze Learning | 1 | 2020 | 478 | 0.160 |
Why?
|
Pyrimidinones | 1 | 2020 | 370 | 0.160 |
Why?
|
Anilides | 1 | 2021 | 408 | 0.150 |
Why?
|
Meningeal Neoplasms | 1 | 2007 | 1241 | 0.150 |
Why?
|
Magnetic Resonance Imaging | 13 | 2020 | 35425 | 0.150 |
Why?
|
Stem Cell Transplantation | 1 | 2006 | 1620 | 0.150 |
Why?
|
Huntington Disease | 1 | 2004 | 1124 | 0.150 |
Why?
|
Neoplasm Recurrence, Local | 6 | 2021 | 9240 | 0.150 |
Why?
|
Radiography | 4 | 2013 | 7023 | 0.140 |
Why?
|
Disease Progression | 6 | 2023 | 13286 | 0.140 |
Why?
|
Psychotropic Drugs | 2 | 2012 | 894 | 0.140 |
Why?
|
Cerebellar Neoplasms | 2 | 2019 | 587 | 0.140 |
Why?
|
Scoliosis | 1 | 2023 | 725 | 0.140 |
Why?
|
Optic Nerve Neoplasms | 1 | 2016 | 44 | 0.140 |
Why?
|
Antiemetics | 1 | 2017 | 177 | 0.140 |
Why?
|
Leukoencephalopathies | 1 | 2019 | 238 | 0.140 |
Why?
|
Positron-Emission Tomography | 1 | 2012 | 6234 | 0.130 |
Why?
|
Codon | 1 | 2017 | 611 | 0.130 |
Why?
|
Bacillus cereus | 1 | 2015 | 35 | 0.130 |
Why?
|
Prospective Studies | 13 | 2024 | 53290 | 0.130 |
Why?
|
Rhabdoid Tumor | 2 | 2008 | 212 | 0.130 |
Why?
|
Pyridones | 1 | 2020 | 711 | 0.130 |
Why?
|
Clinical Competence | 1 | 2011 | 4687 | 0.130 |
Why?
|
Prognosis | 11 | 2020 | 29060 | 0.130 |
Why?
|
Tibia | 2 | 2021 | 1077 | 0.130 |
Why?
|
Follow-Up Studies | 14 | 2020 | 39052 | 0.130 |
Why?
|
Twins, Monozygotic | 1 | 2016 | 458 | 0.130 |
Why?
|
NK Cell Lectin-Like Receptor Subfamily K | 1 | 2015 | 91 | 0.130 |
Why?
|
Incidental Findings | 1 | 2020 | 689 | 0.130 |
Why?
|
Models, Educational | 1 | 2017 | 377 | 0.120 |
Why?
|
Hyperalgesia | 1 | 2019 | 502 | 0.120 |
Why?
|
Telemedicine | 2 | 2023 | 2872 | 0.120 |
Why?
|
Social Behavior | 1 | 2021 | 1127 | 0.120 |
Why?
|
Patch-Clamp Techniques | 4 | 1998 | 964 | 0.120 |
Why?
|
Pravastatin | 1 | 2016 | 395 | 0.120 |
Why?
|
Survival Rate | 8 | 2019 | 12788 | 0.120 |
Why?
|
Visual Fields | 1 | 2020 | 1047 | 0.120 |
Why?
|
Oculomotor Muscles | 1 | 2017 | 371 | 0.120 |
Why?
|
Lamin Type A | 1 | 2015 | 190 | 0.120 |
Why?
|
Protein Kinase Inhibitors | 4 | 2022 | 5534 | 0.120 |
Why?
|
GPI-Linked Proteins | 1 | 2015 | 435 | 0.120 |
Why?
|
Risk Factors | 11 | 2018 | 72296 | 0.110 |
Why?
|
Chlorides | 1 | 1996 | 667 | 0.110 |
Why?
|
Antibodies, Monoclonal | 1 | 2010 | 9274 | 0.110 |
Why?
|
Postoperative Care | 1 | 2020 | 1487 | 0.110 |
Why?
|
Vision Tests | 1 | 2013 | 167 | 0.110 |
Why?
|
Transforming Growth Factor beta | 1 | 2021 | 2007 | 0.110 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2008 | 3524 | 0.110 |
Why?
|
Peripheral Nervous System Diseases | 1 | 2018 | 685 | 0.110 |
Why?
|
Farnesyltranstransferase | 1 | 2012 | 76 | 0.110 |
Why?
|
Interferon-alpha | 1 | 2017 | 895 | 0.110 |
Why?
|
Tumor Cells, Cultured | 6 | 1998 | 6313 | 0.110 |
Why?
|
Cytoskeleton | 1 | 1997 | 1185 | 0.110 |
Why?
|
Rare Diseases | 3 | 2022 | 553 | 0.100 |
Why?
|
Faculty, Medical | 2 | 2012 | 1181 | 0.100 |
Why?
|
Visual Pathways | 1 | 2016 | 565 | 0.100 |
Why?
|
Executive Function | 2 | 2019 | 1364 | 0.100 |
Why?
|
Diphosphonates | 1 | 2016 | 623 | 0.100 |
Why?
|
Attention | 3 | 2016 | 2397 | 0.100 |
Why?
|
Feasibility Studies | 2 | 2020 | 5077 | 0.100 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2020 | 2110 | 0.100 |
Why?
|
Polyethylene Glycols | 1 | 2017 | 1182 | 0.100 |
Why?
|
Surgery, Computer-Assisted | 1 | 2019 | 1018 | 0.100 |
Why?
|
Liver Neoplasms | 1 | 2007 | 4253 | 0.100 |
Why?
|
Cytotoxicity, Immunologic | 1 | 2015 | 1369 | 0.100 |
Why?
|
Brain Diseases | 1 | 2020 | 1563 | 0.090 |
Why?
|
Orthopedic Procedures | 1 | 2021 | 1289 | 0.090 |
Why?
|
Aspirin | 1 | 2022 | 3283 | 0.090 |
Why?
|
Immunocompromised Host | 1 | 2015 | 847 | 0.090 |
Why?
|
Recoverin | 1 | 2009 | 13 | 0.090 |
Why?
|
Protein Isoforms | 1 | 2015 | 1730 | 0.090 |
Why?
|
Imidazoles | 1 | 2016 | 1206 | 0.090 |
Why?
|
Attention Deficit Disorder with Hyperactivity | 3 | 2021 | 3658 | 0.090 |
Why?
|
Stress, Psychological | 2 | 2017 | 4245 | 0.090 |
Why?
|
Germinoma | 1 | 2010 | 134 | 0.090 |
Why?
|
DNA Methylation | 2 | 2023 | 4285 | 0.090 |
Why?
|
Attitude of Health Personnel | 1 | 2003 | 3841 | 0.090 |
Why?
|
Chlamydomonas reinhardtii | 1 | 2009 | 33 | 0.090 |
Why?
|
Starch | 1 | 2009 | 81 | 0.090 |
Why?
|
DNA Modification Methylases | 1 | 2010 | 206 | 0.090 |
Why?
|
Obesity, Morbid | 1 | 2020 | 1213 | 0.090 |
Why?
|
Cognition | 4 | 2021 | 6770 | 0.080 |
Why?
|
Cell Cycle | 1 | 1997 | 2967 | 0.080 |
Why?
|
Disease-Free Survival | 6 | 2016 | 6896 | 0.080 |
Why?
|
Meningioma | 1 | 2018 | 1209 | 0.080 |
Why?
|
Age Factors | 4 | 2014 | 18373 | 0.080 |
Why?
|
Asymptomatic Diseases | 1 | 2011 | 551 | 0.080 |
Why?
|
Research | 2 | 2014 | 1999 | 0.080 |
Why?
|
Histocompatibility Antigens Class I | 1 | 2015 | 1366 | 0.080 |
Why?
|
Patient Selection | 1 | 2021 | 4216 | 0.080 |
Why?
|
Cross-Sectional Studies | 6 | 2024 | 25039 | 0.080 |
Why?
|
Base Sequence | 2 | 2020 | 12797 | 0.080 |
Why?
|
DNA Repair Enzymes | 1 | 2010 | 349 | 0.080 |
Why?
|
Alleles | 1 | 2019 | 6933 | 0.080 |
Why?
|
Retinal Detachment | 1 | 2012 | 411 | 0.080 |
Why?
|
Infant, Newborn | 5 | 2020 | 25628 | 0.080 |
Why?
|
DNA Copy Number Variations | 1 | 2016 | 1941 | 0.080 |
Why?
|
Pinealoma | 1 | 2008 | 54 | 0.080 |
Why?
|
Biomedical Research | 1 | 2003 | 3309 | 0.080 |
Why?
|
Organ Size | 1 | 2013 | 2251 | 0.080 |
Why?
|
Disease Management | 2 | 2018 | 2460 | 0.080 |
Why?
|
Ligands | 1 | 2015 | 3282 | 0.080 |
Why?
|
Heterozygote | 3 | 2019 | 2804 | 0.080 |
Why?
|
Brain | 3 | 2020 | 26388 | 0.080 |
Why?
|
Spinal Cord | 1 | 2016 | 1810 | 0.080 |
Why?
|
Scorpion Venoms | 2 | 1998 | 31 | 0.080 |
Why?
|
Intercellular Signaling Peptides and Proteins | 1 | 2015 | 1677 | 0.080 |
Why?
|
Spinal Neoplasms | 1 | 2014 | 760 | 0.080 |
Why?
|
Down-Regulation | 1 | 2015 | 3001 | 0.070 |
Why?
|
Mentors | 1 | 2012 | 631 | 0.070 |
Why?
|
Circle of Willis | 1 | 2007 | 68 | 0.070 |
Why?
|
Pineal Gland | 1 | 2008 | 166 | 0.070 |
Why?
|
Cohort Studies | 6 | 2020 | 40559 | 0.070 |
Why?
|
Combined Modality Therapy | 5 | 2017 | 8642 | 0.070 |
Why?
|
Optic Chiasm | 1 | 2007 | 87 | 0.070 |
Why?
|
Choroid Plexus Neoplasms | 1 | 2006 | 43 | 0.070 |
Why?
|
Health Promotion | 1 | 2019 | 2205 | 0.070 |
Why?
|
Heart Defects, Congenital | 1 | 2003 | 4583 | 0.070 |
Why?
|
Transfection | 1 | 2015 | 5895 | 0.070 |
Why?
|
Morbidity | 2 | 2023 | 1768 | 0.070 |
Why?
|
Chronic Disease | 2 | 2021 | 9145 | 0.070 |
Why?
|
Head | 1 | 2012 | 880 | 0.070 |
Why?
|
In Situ Hybridization | 1 | 2010 | 1950 | 0.070 |
Why?
|
Psychomotor Performance | 1 | 2014 | 1901 | 0.070 |
Why?
|
Teratoma | 1 | 2008 | 395 | 0.070 |
Why?
|
Vomiting | 2 | 2023 | 637 | 0.070 |
Why?
|
Up-Regulation | 1 | 2015 | 4222 | 0.070 |
Why?
|
Gene Dosage | 1 | 2010 | 1252 | 0.070 |
Why?
|
Polysomnography | 1 | 2012 | 1776 | 0.070 |
Why?
|
Incidence | 3 | 2015 | 20952 | 0.070 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 2007 | 876 | 0.060 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 1 | 2010 | 501 | 0.060 |
Why?
|
Cell Membrane | 1 | 2015 | 3749 | 0.060 |
Why?
|
Antiviral Agents | 1 | 2017 | 2987 | 0.060 |
Why?
|
PTEN Phosphohydrolase | 1 | 2010 | 1142 | 0.060 |
Why?
|
Intelligence | 1 | 2009 | 920 | 0.060 |
Why?
|
Hospitals | 1 | 2018 | 3954 | 0.060 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2021 | 9955 | 0.060 |
Why?
|
Kaplan-Meier Estimate | 2 | 2014 | 6539 | 0.060 |
Why?
|
Prejudice | 1 | 2008 | 570 | 0.060 |
Why?
|
Cyanosis | 1 | 2003 | 83 | 0.060 |
Why?
|
Pain | 1 | 2019 | 4988 | 0.060 |
Why?
|
Research Support as Topic | 1 | 2008 | 705 | 0.060 |
Why?
|
Palliative Care | 1 | 2018 | 3493 | 0.060 |
Why?
|
Genetic Predisposition to Disease | 3 | 2019 | 17446 | 0.060 |
Why?
|
Disease Models, Animal | 3 | 2021 | 18034 | 0.060 |
Why?
|
Protein Binding | 1 | 2015 | 9384 | 0.060 |
Why?
|
Autopsy | 1 | 2007 | 1020 | 0.060 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2021 | 5445 | 0.060 |
Why?
|
Drug Prescriptions | 1 | 2012 | 1637 | 0.060 |
Why?
|
Hydrocephalus | 1 | 2009 | 748 | 0.060 |
Why?
|
Research Personnel | 1 | 2008 | 573 | 0.050 |
Why?
|
Molecular Biology | 1 | 2006 | 596 | 0.050 |
Why?
|
Age of Onset | 2 | 2012 | 3270 | 0.050 |
Why?
|
Polycythemia | 1 | 2003 | 126 | 0.050 |
Why?
|
Occipital Lobe | 1 | 2004 | 379 | 0.050 |
Why?
|
Molecular Sequence Data | 1 | 2015 | 18111 | 0.050 |
Why?
|
Lung Neoplasms | 1 | 2007 | 13104 | 0.050 |
Why?
|
Animals | 9 | 2021 | 168768 | 0.050 |
Why?
|
Biopsy | 2 | 2008 | 6755 | 0.050 |
Why?
|
Fatal Outcome | 1 | 2007 | 1851 | 0.050 |
Why?
|
Stress, Physiological | 1 | 2009 | 1403 | 0.050 |
Why?
|
Radiopharmaceuticals | 1 | 2012 | 2645 | 0.050 |
Why?
|
Time Factors | 5 | 2014 | 40075 | 0.050 |
Why?
|
Pilot Projects | 2 | 2018 | 8319 | 0.050 |
Why?
|
Academic Medical Centers | 1 | 2012 | 2760 | 0.050 |
Why?
|
Physicians, Women | 1 | 2008 | 486 | 0.050 |
Why?
|
Headache | 1 | 2009 | 1226 | 0.050 |
Why?
|
Enzyme Inhibitors | 1 | 2012 | 3799 | 0.050 |
Why?
|
Reproducibility of Results | 1 | 2019 | 19905 | 0.050 |
Why?
|
Thalidomide | 1 | 2006 | 890 | 0.050 |
Why?
|
Drug Design | 1 | 2006 | 1076 | 0.050 |
Why?
|
Lipid Metabolism | 1 | 2009 | 1889 | 0.050 |
Why?
|
Middle Aged | 8 | 2021 | 213390 | 0.050 |
Why?
|
Population Surveillance | 1 | 2011 | 2616 | 0.050 |
Why?
|
Genes, Neurofibromatosis 1 | 1 | 2021 | 79 | 0.050 |
Why?
|
Nerve Fibers | 1 | 2024 | 687 | 0.050 |
Why?
|
Carotid Arteries | 2 | 2016 | 950 | 0.040 |
Why?
|
Pain Measurement | 2 | 2021 | 3420 | 0.040 |
Why?
|
Survival Analysis | 2 | 2017 | 10252 | 0.040 |
Why?
|
Tumor Suppressor Proteins | 1 | 2010 | 2850 | 0.040 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2010 | 2949 | 0.040 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2015 | 8432 | 0.040 |
Why?
|
Fellowships and Scholarships | 1 | 2008 | 1078 | 0.040 |
Why?
|
Research Report | 2 | 2012 | 355 | 0.040 |
Why?
|
Cell Division | 2 | 1997 | 4569 | 0.040 |
Why?
|
Recombinant Proteins | 2 | 2021 | 6621 | 0.040 |
Why?
|
Boston | 2 | 2014 | 9312 | 0.040 |
Why?
|
Cell Line, Tumor | 1 | 2015 | 16690 | 0.040 |
Why?
|
Lipids | 1 | 2009 | 3307 | 0.040 |
Why?
|
Retinal Ganglion Cells | 1 | 2024 | 770 | 0.040 |
Why?
|
Hypotonic Solutions | 1 | 1997 | 49 | 0.040 |
Why?
|
Thymidine | 1 | 1997 | 310 | 0.040 |
Why?
|
Comorbidity | 2 | 2014 | 10388 | 0.040 |
Why?
|
Mice, Mutant Strains | 1 | 2021 | 1865 | 0.040 |
Why?
|
Sample Size | 1 | 2021 | 845 | 0.040 |
Why?
|
Dose-Response Relationship, Drug | 3 | 2019 | 10943 | 0.040 |
Why?
|
Neurotoxins | 1 | 1998 | 237 | 0.040 |
Why?
|
Predictive Value of Tests | 1 | 2013 | 15078 | 0.040 |
Why?
|
Nystagmus, Pathologic | 1 | 2017 | 96 | 0.040 |
Why?
|
Membrane Potentials | 2 | 1997 | 1137 | 0.040 |
Why?
|
Recurrence | 1 | 2008 | 8340 | 0.040 |
Why?
|
4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid | 1 | 1996 | 60 | 0.040 |
Why?
|
Protein Prenylation | 1 | 2016 | 73 | 0.040 |
Why?
|
Immunohistochemistry | 1 | 2010 | 11366 | 0.040 |
Why?
|
Genetic Heterogeneity | 1 | 2020 | 733 | 0.030 |
Why?
|
Phenotype | 3 | 2019 | 16367 | 0.030 |
Why?
|
Neoplasm Metastasis | 1 | 2007 | 4851 | 0.030 |
Why?
|
Spine | 1 | 2023 | 1144 | 0.030 |
Why?
|
Mutation | 3 | 2016 | 29786 | 0.030 |
Why?
|
Genomics | 2 | 2023 | 5717 | 0.030 |
Why?
|
Bone Morphogenetic Proteins | 1 | 2021 | 838 | 0.030 |
Why?
|
Electric Conductivity | 1 | 1996 | 411 | 0.030 |
Why?
|
Stilbenes | 1 | 1996 | 155 | 0.030 |
Why?
|
Mice | 3 | 2021 | 81201 | 0.030 |
Why?
|
Longitudinal Studies | 2 | 2024 | 13991 | 0.030 |
Why?
|
Pain Threshold | 1 | 2019 | 584 | 0.030 |
Why?
|
Amino Acid Substitution | 1 | 2019 | 1793 | 0.030 |
Why?
|
Double-Blind Method | 2 | 2019 | 12025 | 0.030 |
Why?
|
Education, Special | 1 | 2014 | 87 | 0.030 |
Why?
|
Logistic Models | 2 | 2012 | 13409 | 0.030 |
Why?
|
Indans | 1 | 2014 | 96 | 0.030 |
Why?
|
Anticonvulsants | 1 | 2024 | 1916 | 0.030 |
Why?
|
Single-Blind Method | 1 | 2017 | 1590 | 0.030 |
Why?
|
Sequence Deletion | 1 | 2018 | 1525 | 0.030 |
Why?
|
Injections, Spinal | 1 | 2014 | 303 | 0.030 |
Why?
|
Strabismus | 1 | 2017 | 287 | 0.030 |
Why?
|
Nootropic Agents | 1 | 2014 | 160 | 0.030 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2018 | 602 | 0.030 |
Why?
|
Tetrodotoxin | 1 | 1994 | 259 | 0.030 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2021 | 1660 | 0.030 |
Why?
|
Demography | 1 | 2017 | 1655 | 0.030 |
Why?
|
United States | 5 | 2022 | 69872 | 0.030 |
Why?
|
Mice, SCID | 1 | 1998 | 2716 | 0.030 |
Why?
|
Histones | 1 | 2023 | 2598 | 0.030 |
Why?
|
Aged | 4 | 2021 | 163288 | 0.030 |
Why?
|
Antioxidants | 1 | 2020 | 1659 | 0.030 |
Why?
|
SEER Program | 1 | 2017 | 1507 | 0.030 |
Why?
|
Sodium Channels | 1 | 1994 | 349 | 0.030 |
Why?
|
Disease Susceptibility | 1 | 2019 | 1782 | 0.030 |
Why?
|
Language | 1 | 2021 | 1471 | 0.030 |
Why?
|
Women, Working | 1 | 2012 | 87 | 0.030 |
Why?
|
Ganglia, Spinal | 1 | 1994 | 519 | 0.020 |
Why?
|
Cerebellum | 1 | 2019 | 1488 | 0.020 |
Why?
|
Sodium-Potassium-Exchanging ATPase | 1 | 1994 | 494 | 0.020 |
Why?
|
Tomography, Optical Coherence | 1 | 2024 | 2657 | 0.020 |
Why?
|
Thinking | 1 | 2014 | 318 | 0.020 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2012 | 11525 | 0.020 |
Why?
|
Caregivers | 1 | 2023 | 2095 | 0.020 |
Why?
|
Delivery of Health Care | 2 | 2023 | 5321 | 0.020 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2014 | 640 | 0.020 |
Why?
|
Bone Density | 1 | 2023 | 3468 | 0.020 |
Why?
|
Vinblastine | 1 | 2012 | 502 | 0.020 |
Why?
|
Health Services Needs and Demand | 1 | 2018 | 1410 | 0.020 |
Why?
|
Algal Proteins | 1 | 2009 | 7 | 0.020 |
Why?
|
Methylphenidate | 1 | 2014 | 473 | 0.020 |
Why?
|
alpha-Fetoproteins | 1 | 2010 | 224 | 0.020 |
Why?
|
Chromatography, Thin Layer | 1 | 2009 | 223 | 0.020 |
Why?
|
Vincristine | 1 | 2012 | 1039 | 0.020 |
Why?
|
Chromatography, Gas | 1 | 2009 | 156 | 0.020 |
Why?
|
Aged, 80 and over | 1 | 2015 | 57776 | 0.020 |
Why?
|
Actins | 1 | 1997 | 2121 | 0.020 |
Why?
|
Transplantation, Heterologous | 1 | 1998 | 2383 | 0.020 |
Why?
|
Congresses as Topic | 1 | 2014 | 764 | 0.020 |
Why?
|
Obesity | 1 | 2012 | 12746 | 0.020 |
Why?
|
Postoperative Period | 1 | 2014 | 1842 | 0.020 |
Why?
|
Human Growth Hormone | 1 | 2014 | 683 | 0.020 |
Why?
|
Cardiovascular Diseases | 1 | 2015 | 15160 | 0.020 |
Why?
|
Carboplatin | 1 | 2012 | 801 | 0.020 |
Why?
|
Nitrogen | 1 | 2009 | 344 | 0.020 |
Why?
|
Patient Satisfaction | 1 | 2021 | 3395 | 0.020 |
Why?
|
Severity of Illness Index | 2 | 2017 | 15535 | 0.020 |
Why?
|
Genetic Testing | 1 | 2021 | 3444 | 0.020 |
Why?
|
Benzhydryl Compounds | 1 | 2014 | 845 | 0.020 |
Why?
|
Chromosome Mapping | 1 | 2016 | 4740 | 0.020 |
Why?
|
Memory, Short-Term | 1 | 2014 | 977 | 0.020 |
Why?
|
Computational Biology | 1 | 2020 | 3519 | 0.020 |
Why?
|
Radiotherapy Dosage | 1 | 2014 | 2879 | 0.020 |
Why?
|
Methotrexate | 1 | 2014 | 1728 | 0.020 |
Why?
|
Sex Factors | 2 | 2014 | 10400 | 0.020 |
Why?
|
Learning | 1 | 2016 | 1711 | 0.020 |
Why?
|
Early Detection of Cancer | 1 | 2021 | 3086 | 0.020 |
Why?
|
Flow Cytometry | 1 | 1997 | 5974 | 0.020 |
Why?
|
Proteomics | 1 | 2020 | 3638 | 0.020 |
Why?
|
Quality Improvement | 1 | 2022 | 3749 | 0.020 |
Why?
|
Astrocytes | 1 | 1994 | 1273 | 0.020 |
Why?
|
Drug Therapy, Combination | 1 | 2016 | 6489 | 0.020 |
Why?
|
Reference Standards | 1 | 2009 | 1025 | 0.020 |
Why?
|
Central Nervous System Stimulants | 1 | 2014 | 1148 | 0.020 |
Why?
|
Cell Line | 2 | 1997 | 16000 | 0.020 |
Why?
|
Amino Acid Sequence | 1 | 2017 | 13814 | 0.020 |
Why?
|
Bone and Bones | 1 | 2016 | 2576 | 0.020 |
Why?
|
Diarrhea | 1 | 2012 | 1348 | 0.020 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2014 | 1520 | 0.020 |
Why?
|
Staining and Labeling | 1 | 2009 | 1101 | 0.020 |
Why?
|
Fatigue | 1 | 2012 | 1531 | 0.020 |
Why?
|
Drug Therapy | 1 | 2008 | 497 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2012 | 4933 | 0.020 |
Why?
|
Computer Simulation | 1 | 2017 | 6194 | 0.010 |
Why?
|
Salvage Therapy | 1 | 2010 | 1275 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2007 | 20130 | 0.010 |
Why?
|
Awards and Prizes | 1 | 2008 | 375 | 0.010 |
Why?
|
Body Mass Index | 1 | 2020 | 12721 | 0.010 |
Why?
|
Weight Gain | 1 | 2012 | 2293 | 0.010 |
Why?
|
Neoplasm Staging | 1 | 2017 | 11031 | 0.010 |
Why?
|
Mass Spectrometry | 1 | 2009 | 2204 | 0.010 |
Why?
|
Microscopy, Fluorescence | 1 | 2009 | 2700 | 0.010 |
Why?
|
Genotype | 1 | 2016 | 12952 | 0.010 |
Why?
|
Triglycerides | 1 | 2009 | 2453 | 0.010 |
Why?
|
Secondary Prevention | 1 | 2008 | 1530 | 0.010 |
Why?
|
Schools, Medical | 1 | 2008 | 881 | 0.010 |
Why?
|
Pandemics | 1 | 2021 | 8385 | 0.010 |
Why?
|
Treatment Failure | 1 | 2006 | 2618 | 0.010 |
Why?
|
Head and Neck Neoplasms | 1 | 2014 | 2736 | 0.010 |
Why?
|
Cells, Cultured | 2 | 2009 | 19233 | 0.010 |
Why?
|
Genome-Wide Association Study | 1 | 2016 | 12262 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2016 | 15520 | 0.010 |
Why?
|
Prevalence | 1 | 2012 | 15221 | 0.010 |
Why?
|
Strophanthidin | 1 | 1994 | 15 | 0.010 |
Why?
|
Rubidium | 1 | 1994 | 133 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2009 | 14723 | 0.010 |
Why?
|
Ouabain | 1 | 1994 | 264 | 0.010 |
Why?
|
Electrophysiology | 1 | 1994 | 1308 | 0.010 |
Why?
|
Sodium | 1 | 1994 | 1622 | 0.010 |
Why?
|
Animals, Newborn | 1 | 1994 | 2726 | 0.010 |
Why?
|
Rats, Sprague-Dawley | 1 | 1994 | 8300 | 0.000 |
Why?
|
Rats | 1 | 1994 | 24252 | 0.000 |
Why?
|
Models, Biological | 1 | 1994 | 9584 | 0.000 |
Why?
|